Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Capital Expenditures (2023 - 2025)

Metagenomi (MGX) has disclosed Capital Expenditures for 3 consecutive years, with $502000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 50.3% to $502000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $574000.0, a 81.57% decrease, with the full-year FY2025 number at $574000.0, down 81.57% from a year prior.
  • Capital Expenditures was $502000.0 for Q4 2025 at Metagenomi, up from $31000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.2 million in Q2 2023 to a low of -$247000.0 in Q2 2025.
  • A 3-year average of $1.1 million and a median of $790000.0 in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 50.3% in 2025; the steepest drop was 137.14% in 2025.
  • Metagenomi's Capital Expenditures stood at $1.7 million in 2023, then crashed by 80.77% to $334000.0 in 2024, then skyrocketed by 50.3% to $502000.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Capital Expenditures are $502000.0 (Q4 2025), $31000.0 (Q3 2025), and -$247000.0 (Q2 2025).